Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Brazil ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Ishares Msci Brazil ETF trades at $33.89. The key difference: Ishares Msci Brazil ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWZ | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $41.75 |
52-Week Low | $205.48 | $27.36 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
EWZ, the iShares MSCI Brazil ETF, trades at $33.86, down 3.78% in the last session. Technical indicators are bearish overall, with moving averages signaling sell pressure, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC taking a $3.06 million position as of August 5, 2026, and Allspring Global Investments increasing its stake significantly in July 2026. The fund offers exposure to Brazilian equities, with a dividend announced for June 2026.
The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist for value-seeking investors given Brazil's market potential, but risks include U.S. tariff impacts (Reuters, July 16, 2026) and competition from lower-cost ETFs like FLBR, which offers a higher dividend yield (Seeking Alpha, July 16, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
